These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31315877)

  • 1. Factors associated with PPSV23 coverage among older adults in Japan: a nationwide community-based survey.
    Murakami Y; Kanazu S; Petigara T; Oba MS; Nishiwaki Y; Watanabe A
    BMJ Open; 2019 Jul; 9(7):e030197. PubMed ID: 31315877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older.
    Kawakami K; Nakamura A; Wakana A; Folaranmi TA; Iino T
    Hum Vaccin Immunother; 2020 Jul; 16(7):1521-1528. PubMed ID: 31799889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) revaccination coverage rate among elderly adults aged 65 and older and physician's attitude.
    Nakamura A; Kawakami K; Wakana A; Folaranmi TA; Iino T
    Hum Vaccin Immunother; 2020 Sep; 16(9):2292-2299. PubMed ID: 32045317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Social capital and pneumococcal vaccination (PPSV23) in community-dwelling older Japanese: a JAGES multilevel cross-sectional study.
    Iwai-Saito K; Shobugawa Y; Kondo K
    BMJ Open; 2021 Jun; 11(6):e043723. PubMed ID: 34140341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017.
    Vila-Córcoles A; Ochoa-Gondar O; de Diego C; Satué E; Vila-Rovira A; Aragón M
    Euro Surveill; 2019 Jul; 24(29):. PubMed ID: 31339099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
    Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
    Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The estimated impact of the 5-year national vaccination program on the trend of 23-valent pneumococcal polysaccharide vaccine vaccination rates in the elderly in Japan, 2009-2018.
    Naito T; Suzuki M; Fujibayashi K; Kanazawa A; Takahashi H; Yokokawa H; Watanabe A
    J Infect Chemother; 2020 Apr; 26(4):407-410. PubMed ID: 31924523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact on vaccination coverage following introduction of a routine pneumococcal vaccination programme for the elderly in Japan.
    Shono A; Hoshi SL; Kondo M
    Vaccine; 2018 Sep; 36(39):5886-5890. PubMed ID: 30143271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the national routine vaccination program on 23-valent pneumococcal polysaccharide vaccine vaccination rates in elderly persons in Japan.
    Naito T; Yokokawa H; Watanabe A
    J Infect Chemother; 2018 Jun; 24(6):496-498. PubMed ID: 29398479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination pattern of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Hangzhou, China: a coverage and adverse events following immunization of different age groups.
    Liu Y; Xu Y; Wang J; Che X; Gu W; Du J; Zhang X; Zhang X; Jiang W; Chen J; An Z
    Hum Vaccin Immunother; 2021 Jan; 17(1):157-161. PubMed ID: 32530728
    [No Abstract]   [Full Text] [Related]  

  • 11. Pneumococcal vaccination, but not influenza vaccination, is negatively associated with incident dementia among Japanese older adults: The JAGES 2013-2022 prospective cohort study.
    Iwai-Saito K; Sato K; Fujii M; Kondo K
    Brain Behav Immun; 2024 Aug; 120():452-463. PubMed ID: 38925416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.
    Nakashima K; Aoshima M; Ohfuji S; Yamawaki S; Nemoto M; Hasegawa S; Noma S; Misawa M; Hosokawa N; Yaegashi M; Otsuka Y
    Hum Vaccin Immunother; 2018; 14(8):1923-1930. PubMed ID: 29561248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal vaccine coverage in Japan among patients with a history of splenectomy: Results of a retrospective administrative database study.
    Yamada M; Li M; Iino T
    Vaccine; 2021 May; 39(19):2692-2697. PubMed ID: 33865627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between family physician's direct advice and pneumococcal vaccination intention and behavior among the elderly in Japan: a cross-sectional study.
    Higuchi M; Narumoto K; Goto T; Inoue M
    BMC Fam Pract; 2018 Sep; 19(1):153. PubMed ID: 30185157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake of pneumococcal polysaccharide vaccination among working-age adults with underlying medical conditions, United States, 2009.
    Lu PJ; Nuorti JP
    Am J Epidemiol; 2012 Apr; 175(8):827-37. PubMed ID: 22403807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of pneumococcal and influenza vaccination coverage in rheumatology patients receiving biological therapy in a regional referral hospital.
    Fernández-Prada M; Brandy-García AM; Rodríguez-Fonseca OD; Huerta-González I; Fernández-Noval F; Martínez-Ortega C
    Reumatol Clin (Engl Ed); 2020; 16(2 Pt 1):97-102. PubMed ID: 29752214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Coverage With Influenza, Pneumococcal, and Herpes Zoster Vaccines Among Patients With Rheumatic Diseases in a Nationwide Healthcare Plan.
    Furer V; Weil C; Chodik G; Slav SA; Blonder SN; Fisher-Shoval Y; Barak M; Elkayam O
    J Rheumatol; 2024 May; 51(5):505-516. PubMed ID: 38302167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis.
    Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    Hum Vaccin Immunother; 2019; 15(4):863-872. PubMed ID: 30633706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.